Sunitinib or pazopanib: Is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma?

Basit Öğe Kaydı
dc.authorid0000-0002-4597-9721en_US
dc.contributor.authorUçar, Gökhan
dc.contributor.authorAçıkgöz, Yusuf
dc.contributor.authorErgun, Yakup
dc.contributor.authorBal, Öznur
dc.contributor.authorYılmaz, Mesut
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKöstek, Osman
dc.contributor.authorIsak, Özlem Aydın
dc.contributor.authorŞener, Görkem Yazıcı
dc.contributor.authorDirikoç, Merve
dc.contributor.authorEsen, Selin Aktürk
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorUncu, Doğan
dc.date.accessioned2021-09-03T12:03:25Z
dc.date.available2021-09-03T12:03:25Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.descriptionWOS:000570786000006
dc.descriptionPMID: 33094066
dc.description.abstractIntroduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-nivolumab tyrosine kinase inhibitors (TKIs). Material and methods The analysis of patients was performed after all cohorts were sub-grouped into two groups according to pre-nivolumab TKIs as following the sunitinib arm and the pazopanib arm. Result A total of 75 patients were included in this study. The median follow-up time was eight months for all cohorts. The objective response rate was statistically significantly higher in the pazopanib arm as compared to the sunitinib arm (56% vs 30%, p=0.02). Progression-free survival was significantly higher in pazopanib than sunitinib (10.3 months vs 5.3 months, p=0.02). Multivariate analysis revealed that pazopanib treatment was associated with better progression-free survival (HR: 0.44, 95 CI; 0.22-0.91, p=0.02). While the median overall survival for patients who had received sunitinib was 11.0 months, it has not been reached the median in the pazopanib arm (11.0 months vs NR, p=0.051). Discussion We demonstrated significantly better progression-free survival and a higher objective response rate with nivolumab treatment in patients who had received pazopanib as compared with patients who received sunitinib in the pre-nivolumab period.en_US
dc.identifier.citationUçar, G., Açıkgöz, Y., Ergun, Y., Bal, Ö., Yılmaz, M., Karakaya, S. ve diğerleri. (2020). Sunitinib or pazopanib: Is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma? Cureus, 12(9), 1-9.en_US
dc.identifier.doi10.7759/cureus.10525
dc.identifier.endpage9en_US
dc.identifier.issn2168-8184
dc.identifier.issue9en_US
dc.identifier.pmid33094066
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574822/pdf/cureus-0012-00000010525.pdf
dc.identifier.urihttps://hdl.handle.net/11468/7430
dc.identifier.volume12en_US
dc.identifier.wosWOS:000570786000006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorAkdeniz, Nadiye
dc.language.isoenen_US
dc.publisherCureus Inc.en_US
dc.relation.ispartofCureus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal cell carcinomaen_US
dc.subjectMetastasisen_US
dc.subjectSunitiniben_US
dc.subjectPazopaniben_US
dc.subjectNivolumaben_US
dc.titleSunitinib or pazopanib: Is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma?en_US
dc.titleSunitinib or pazopanib: Is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma?
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
cureus-0012-00000010525.pdf
Boyut:
307.07 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu